How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression

Journal of Psychiatric Practice

Volumn 18, Issue 4, 2012, Pages 281-286

  MacAluso, Matthew ^a   Drevets, Wayne C ^b   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

Author keywords

11 dehydroxy thromboxane B2; biomarkers; coronary artery disease; COX 2 inhibitors; inflammatory markers; thromboxane

Indexed keywords

11 DEHYDROXY THROMBOXANE B2; ALPHA INTERFERON; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; OMEGA 3 FATTY ACID; PEPTIDASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SERTRALINE; THROMBOXANE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BECK DEPRESSION INVENTORY; COMORBIDITY; CORONARY ARTERY DISEASE; DENDRITE; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; ENZYME INACTIVATION; EXCITOTOXICITY; FATTY ACID BLOOD LEVEL; HEART DISEASE; HUMAN; INFLAMMATION; MAJOR DEPRESSION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOLOGICAL MARKERS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; MENTAL DISORDERS; SENSITIVITY AND SPECIFICITY; THROMBOXANE B2;

EID: 84863951909     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000416018.83709.3e     Document Type: Article

References (24)

1. Macaluso M, Preskorn SH. How biomarkers will change psychiatry: From clinical trials to practice. Part I; Introduction. J Psychiatr Pract 2012;18:118-21.
2. Preskorn SH. The use of biomarkers in psychiatric research: How serotonin transporter occupancy explains the dose-response curves of SSRIs. J Psychiatr Pract 2012;18:38-45.
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
4. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005;65:1863-72. (Pubitemid 43970103)
5. Javitt DC, Doneshka P, Zylberman I, et al. Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study. Biol Psychiatry 1993;33: 513-9. (Pubitemid 23167217)
6. Miller GE, Stetler CA, Carney RM, et al. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002;90:1279-83. (Pubitemid 35449470)
7. Lespérance F, Frasure-Smith N. Depression in patients with cardiac disease: A practical review. J Psychosom Res 2000;48:379-91. (Pubitemid 30433396)
8. Dantzer R, O'Connor JC, Freund GC, et al. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-57.
9. Serebruany VL, Glassman AH, Malinin AI. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-44. (Pubitemid 37048222)
10. Lieb J, Karmali R, Horrobin D. Elevated levels of prosta -glandin e2 and thromboxane B2 in depression. Prostaglandins: Leukot Med 1983;10:361-7. (Pubitemid 13162267)
11. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27-53.
12. Kubera M, Obuchowicz E, Goehler L, et al. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:744-59.
13. Galecki P, Florkowski A, Bienkiewicz M, et al. Functional polymorphisms of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 2010;62:116-20.
14. Drexhage RC, Knijff EM, Padmos RC, et al. The mononu-clear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010;10:59-76.
15. Muller N, Myint AM, Schwarz MJ. Inflammatory biomark-ers and depression. Neurotox Res 2011;19:308-18.
16. Chen C-Y, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsy-chological dysfunction. Gen Hosp Psychiatry 2010;32:647, e7-9.
17. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94. (Pubitemid 351359580)
18. Bruno A, McConnell JP, Mansbach III, HH, et al. Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients. Stroke 2002;33:57-60. (Pubitemid 34052185)
19. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: Determinants and effect on cardiovascular risk. Circula -tion 2008;118:1705-12.
20. AspirinWorks™ (11-Dehydrothromboxane B2) Test. Test performed on random urine specimen. Increased levels of 11-dehydrothromboxane B2 in urine are an indication that the dosage of aspirin is not effective for decreasing risk of a heart attack or stroke, while decreased levels of 11-dehy-drothromboxane B2 indicate that the aspirin dose is working. (Information on how 11-Dehydrothromboxane B2 can be used in clinical cardiology practice is www.privatemdlabs.com/lp/AspirinWorks.php , accessed July 5, 2012).
21. Bruce EC, Guo Y, Lawson K. Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. Psychosom Med 2008;70: 319-27. (Pubitemid 351543506)
22. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression Arch Gen Psychiatry 1961;4: 561-71.
23. Savitz J, Preskorn S, Teague TK, et al. Minocycline and aspirin in the treatment of bipolar depression: A protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2012;2:e000643 (http://dx.doi.org/10.1136/bmjopen-2011-000643).
24. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease." The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16.